title: Downregulation of EIF4A2 in non-small-cell lung cancer associates with poor prognosis.
abstract: BACKGROUND
  EIF4A2, which belongs to the eukaryotic initiation factor 4A family, is a highly conserved gene for one of the protein-synthesis initiation factors involved in the binding of messenger RNA to the ribosome. The role of EIF4A2 in some cancers, eg, breast cancer and melanoma, has been studied. However, the clinical significance and biologic role of EIF4A2 in lung cancer remains unknown.
  
  
  METHODS
  A total of 170 patients with non-small-cell lung cancer who were undergoing surgical resection were studied. We applied the tissue microarray by using immunohistochemistry to study the expression of EIF4A2 in patients with non-small-cell lung cancer (NSCLC).
  
  
  RESULTS
  We found that the expression rate of EIF4A2 in NSCLC was 87.6%. The expression of EIF4A2 was significantly correlated with the histopathologic classification (P = .049) and tumor grade (P < .019). Moreover, NSCLC patients with low EIF4A2 expression survived shorter than those with high EIF4A2 expression, as indicated by overall survival (P = .023) and disease-free survival (P = .011) assessed by the Kaplan-Meier method. In addition, multivariate analysis suggested EIF4A2 as an independent predictor of disease-free survival (hazard ratio 0.543 [95% CI, 0.329-0.897]; P = .017).
  
  
  CONCLUSIONS
  Collectively, our study demonstrated that EIF4A2 was remarkably involvement in the development of NSCLC and could be served as a potential prognostic marker for patients with this deadly disease.
authors.affiliation: Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Shaoyan
authors.forename: Yong
authors.initials: Y
authors.lastname: Juanjuan
authors.forename: Tao
authors.initials: T
authors.lastname: Yalan
authors.forename: He
authors.initials: H
authors.lastname: Ping
authors.forename: Liang
authors.initials: L
authors.lastname: Jianzhong
authors.forename: Wu
authors.initials: W
authors.lastname: Qinian
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D015536:Down-Regulation; D039601:Eukaryotic Initiation Factor-4A / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D039601:Eukaryotic Initiation Factor-4A
keywords: EIF4A2; Immunohistochemistry; Non–small-cell lung carcinoma; Prognosis